DIRS.INFO The most relevant business & tech news

WASHINGTON, Nov 7 (Reuters) - The U.S. Supreme Court on Monday rebuffed a bid by Bristol Myers Squibb Co's Juno Therapeutics Inc to reinstate a $1.2 billion award it won in its patent fight with Gilead Sciences Inc (GILD.O) subsidiary Kite Pharma Inc over a lymphoma drug. The justices turned away Juno's appeal of a lower court's ruling throwing out the award in the litigation over Kite's biologic drug Yescarta, in a case that could have repercussions for the cutting-edge biologic drug industry. Juno and Sloan Kettering Institute for Cancer Research sued Kite in 2017 in federal court in Los Angeles, accusing it of copying technology that the institute licenses to Juno. Juno and Sloan Kettering have told the Supreme Court that the Federal Circuit's decision to invalidate the patent and other rulings against biologic patents have been "devastating for innovation." On Nov. 4, the Supreme Court took up another patent case involving biologic drugs, agreeing to hear Amgen's bid to revive patents on its cholesterol drug Repatha.

☆ GSK's blood cancer drug fails main goal of trial, shares fall
▼ + stars: | 2022-11-07 | by ( Pushkala Aripaka | ) www.reuters.com time to read: +2 min

SummarySummary Companies Data calls into question existing drug approval -analystsGSK in talks with health authorities, other trials continuingShares fall 3%Nov 7 (Reuters) - GSK's (GSK.L) blood cancer drug Blenrep failed the main goal of a late-stage study designed to show it was better than an existing treatment on the market, the company said on Monday. In April, the company agreed to buy U.S. drug developer Sierra Oncology, gaining access to its main experimental drug for a rare blood cancer and complementing GSK's Blenrep. In the trial, Blenrep was compared with a combination of pomalidomide and low doses of the steroid dexamethasone. Pomalidomide was developed by Celgene, now part of Bristol-Myers Squibb , and was approved in 2013 as a treatment for multiple myeloma. The drug belongs to a promising category of treatments called antibody drug conjugates, which are engineered antibodies that bind to tumour cells and then release cell-killing chemicals.

☆ Stability in a volatile market? Inside an S&P 500 ETF delivering double-digit percentage dividends
▼ + stars: | 2022-11-05 | by ( Noah Sheidlower | ) www.cnbc.com time to read: +2 min

Investors may want to consider JPMorgan's Equity Premium Income Fund ETF in order to get more reliable gains in the current volatile market environment. According to the firm, the ETF uses S&P 500 options and proprietary data to generate monthly income for investors. The goal is to provide investors with income even when market uncertainty is high. The JPMorgan Equity Premium Income Fund ETF is outperforming the S&P 500 year to date. The ETF is down almost 15% while the S&P is off about 21%.

☆ The market could be anticipating a Republican sweep of Congress in Tuesday’s election
▼ + stars: | 2022-11-05 | by ( Patti Domm | In | ) www.cnbc.com time to read: +2 min

The Strategas Republican portfolio contains a number of energy companies including Cheniere, Centrus Energy , Enterprise Products and ConocoPhillips. The Republican portfolio contains Regeneron , up 7.5% since the end of September, and Bristol-Myers Squibb, up 10.8% in that same period. Clifton said the Republican portfolio bottomed out around Sept. 7, and in October it pulled ahead. "There's more confidence the Republican House gains are going to be quite large," he said. "If the consensus is wrong and the Democrats keep the Senate, the sector that will have the most upside is the clean energy sector," he said.

The justices took up Amgen's appeal of the lower court ruling that threw out the Repatha patents. Amgen and other drugmakers have called the case a test of their ability to earn and defend patents for important drugs. Amgen first sued Regeneron and Sanofi in 2014 over their rival drug Praluent, which works by a similar mechanism as Repatha. Thousand Oaks, California-based Amgen sold more than $1.1 billion worth of Repatha worldwide last year. Regeneron sold $170 million worth of Praluent in the United States last year, and Sanofi sold over $200 million worth in the rest of the world.

The COP27 climate summit gets underway in Egypt from Nov. 6. Climate Change Conference will see more than 30,000 delegates convene in the Red Sea resort town of Sharm el-Sheikh to discuss collective action on the climate emergency. Loss and damage funding, meanwhile, is recognized by many as the third pillar of international climate policy. Kerry's openness to talks on loss and damage funding marked an abrupt change in tone from just one month earlier. Singh said political mobilization over loss and damage funding makes COP27 the most important COP yet.

☆ New U.S. cancer drug prices rise 53% in five years -report
▼ + stars: | 2022-11-02 | by ( Deena Beasley | ) www.reuters.com time to read: +4 min

"I do think there is a possibility we see launch prices go up," she said. Reuters GraphicsPorter, who championed inflation-based caps on drug prices, is calling for additional national legislation to link launch prices to how well a drug works. The report found that the average launch price of a self-administered cancer drug, after adjusting for inflation, rose by nearly 26% to $238,000 between 2017 and 2021. By 2022, six out of the eight newly-launched oral cancer drugs had prices over $200,000 per year. Based on current trends, the report calculated that by 2026, when Medicare will first be able to negotiate drug prices, the average self-administered cancer drug launch price will be nearly $325,000 per year and over $525,000 for pills and biologics.

☆ Charity clothing stores turn to Depop and Instagram as they head upmarket with vintage and designer items
▼ + stars: | 2022-10-30 | by ( Grace Dean | ) www.businessinsider.com time to read: +13 min

Britain's charity shops are changing how they look and trying to appeal to Gen Z customers. They're selling more designer and vintage items, creating listings on Depop, and carefully curating their social-media profiles — all targeted mainly at appealing to the growing number of Gen Z shoppers. The managers told Insider their retro and vintage stores were largely in urban areas with large student populations. Non-essential retail stores had to shut their doors for months during the pandemic, which the Charity Retail Association estimates cost UK charity shops about £28 million ($32 million) a month. But, as the aisles of charity shops across the UK show, a lot of people do choose to donate them.

☆ Morning Bid: Consumer drain as banks gain
▼ + stars: | 2022-10-26 | by ( ) www.reuters.com time to read: +5 min

Google's results in particular bode ill for Facebook parent Meta Platforms (META.O), especially reliant on advertising and reporting its results late on Wednesday. Consumer blues contrasted with bumper earnings from banks who are raking in huge windfalls from rising interest rates - direct cash injections from reserves they hold at central banks along with higher net interest margins and trading revenues flattered by volatile markets. read more read more read more read moreEuropean banks reporting this week matched Wall St counterparts on that score, raising conundrums for the European Central Bank meeting this week and Bank of England and U.S. Federal Reserve gatherings next week. They all plan further policy rate rises to rein in inflation - but this also involves direct transfers to their banks and potentially a drain on government finances. They do not reflect the views of Reuters News, which, under the Trust Principles, is committed to integrity, independence, and freedom from bias.

☆ Bristol Myers Squibb CEO: We are on track to continue delivering growth
▼ + stars: | 2022-10-26 | by ( ) www.cnbc.com time to read: 1 min

In this videoShare Share Article via Facebook Share Article via Twitter Share Article via LinkedIn Share Article via EmailBristol Myers Squibb CEO: We are on track to continue delivering growthBristol Myers Squibb CEO Dr. Giovanni Caforio joins CNBC's 'Squawk on the Street' to discuss the company's third-quarter earnings report.

☆ Watch CNBC's full interview with Bristol Myers Squibb CEO Dr. Giovanni Caforio
▼ + stars: | 2022-10-26 | by ( ) www.cnbc.com time to read: 1 min

Share Share Article via Facebook Share Article via Twitter Share Article via LinkedIn Share Article via EmailWatch CNBC's full interview with Bristol Myers Squibb CEO Dr. Giovanni CaforioBristol Myers Squibb CEO Dr. Giovanni Caforio joins CNBC's 'Squawk on the Street' to discuss the company's third-quarter earnings report. Caforio also breaks down the company's portfolio of cardiovascular drugs, including heavyweight Eliquis. "Internationally, business was impacted by exchange," Caforio tells CNBC.

☆ Johnson & Johnson's blood cancer therapy gets U.S. FDA approval
▼ + stars: | 2022-10-25 | by ( Khushi Mandowara | ) www.reuters.com time to read: +2 min

Oct 25 (Reuters) - The U.S. Food and Drug Administration (FDA) has approved Johnson & Johnson's (JNJ.N) therapy for treating a type of multiple myeloma, the company said on Tuesday, giving another treatment option to patients with the incurable blood cancer. Tecvayli is a bispecific antibody, which is engineered to redirect body's immune system to recognize and kill cancer cells. It is the first drug of its class to be approved for multiple myeloma. Though multiple myeloma is rare compared to breast or prostate cancer, it is a common type of blood cancer, which develops in the bone marrow and can spread throughout the body. According to the American Cancer Society's estimates, close to 35,000 new cases of multiple myeloma are likely to be diagnosed in the United States this year.

☆ Luxury hotel booking programs from Amex, Capital One, Visa, and more can get you free elite benefits like room upgrades and on-property credits — here's how
▼ + stars: | 2022-10-25 | by ( Eric Rosen | Tessa Campbell | Read More | ) www.businessinsider.com time to read: +39 min

David Slotnick/Business InsiderMany travel rewards cards offer elite-like hotel benefits when you book with their online portals. The prices through credit card travel portals are often on par with booking directly through hotels. However, it's only available to Capital One Venture X Rewards Credit Card and Capital One Spark Travel Elite cardholders. Bottom lineYou might not have a premium hotel credit card or elite status with one of the major loyalty programs. However, that doesn't mean you can't take advantage of credit card booking portals to enjoy perks like room upgrades, free breakfast, and on-property credits.

☆ The economy may be in better shape than you think...for now
▼ + stars: | 2022-10-23 | by ( Paul R. La Monica | ) edition.cnn.com time to read: +7 min

The consensus forecast from economists surveyed by Reuters is that GDP grew at an annualized pace of 2.1% in the third quarter. (This will be the first estimate for third-quarter GDP, and there will be several revisions in the coming weeks.) That also means the Fed will likely continue to sharply raise interest rates to finally choke off inflation once and for all. Those rate hikes helped cause a so-called double-dip recession, where the economy suffered two downturns between 1980 and 1982. In other words, the much-hoped-for “soft landing” for the economy could turn out to be a pipe dream.

☆ Major gun safety group turns its attention to sheriff races with new ads
▼ + stars: | 2022-10-21 | by ( Https | Media-Cldnry.S-Nbcnews.Com Image Upload Newscms Alex-Seitz-Wald-Circle-Byline-Template.Jpg | Alex Seitz-Wald | ) www.nbcnews.com time to read: +3 min

WASHINGTON — The country’s largest gun safety group is turning its attention down ballot by pumping money into local sheriff races this election. Everytown for Gun Safety, the massive gun control group founded by former New York City Mayor Michael Bloomberg, told NBC News on Friday it's “leaving no stone unturned in the fight to end gun violence” and will spend $300,000 on digital ads in two sheriff races this year. County sheriffs, unlike most law enforcement officers, are directly elected by voters in most parts of the country. “Sheriffs are elected to enforce the law, not make them,” said John Feinblatt, head of Everytown for Gun Safety Victory Fund. The Bernalillo County race in New Mexico race falls along more familiar partisan lines.

☆ Fact Check-Image of Jacob Rees-Mogg at centre of scuffle is from 2018, not alleged House of Commons incident in October 2022
▼ + stars: | 2022-10-21 | by ( Reuters Fact Check | ) www.reuters.com time to read: +1 min

Social media users are sharing a photo of UK Parliamentarian Jacob Rees-Mogg at the centre of a fracas and claiming it shows an alleged scuffle inside the House of Commons on Oct. 19, 2022. However, the picture was taken at an event at the University of the West of England (UWE) on Feb. 2, 2018. One Facebook page (here), uploaded an article (here) which uses a thumbnail image of the British MP in the centre of a group of tussling men. Similar social media posts can be seen on Facebook (here and here) and Twitter (here and here), where the tweets have amassed more than 1,500 shares combined. This article was produced by the Reuters Fact Check team.

☆ Earnings are off to a surprisingly decent start. Next week is the big test for tech
▼ + stars: | 2022-10-21 | by ( Jim Cramer | ) www.cnbc.com time to read: +7 min

Stocks rallied this week as earnings season ramped up and is so far off to a better-than-expected start. With 20% of the S & P 500 having reported financials so far, sales results have thus far been 1.4% above expectations while earnings results are 5.4% above expectations, in aggregate. That inverse correlation between bond yields and stocks was powerful enough to trump positive earnings reports. Looking back On the earnings front, we got results from Johnson & Johnson (JNJ), Procter & Gamble (PG), and Danaher (DHR). As a subscriber to the CNBC Investing Club with Jim Cramer, you will receive a trade alert before Jim makes a trade.

☆ Stocks could continue to break higher as Apple, big tech report earnings in week ahead
▼ + stars: | 2022-10-21 | by ( Patti Domm | In | ) www.cnbc.com time to read: +9 min

The three major averages closed higher Friday, with the S & P 500 adding 2.37% to close at 3,752.75. Stovall said the S & P 500 had six positive moves of 1% or more in the last 17 trading days, as of Friday. Earnings, earnings, earnings About 150 S & P 500 companies report earnings in the coming week. Technically speaking Scott Redler, partner with T3Live.com, said he is watching a formation in the S & P 500 that could be positive. His first target for the S & P 500 is 3,800.

☆ Fact Check-COVID-19 vaccines not linked to 8,200% increase in child deaths in past year, as claimed in online video
▼ + stars: | 2022-10-19 | by ( Reuters Fact Check | ) www.reuters.com time to read: +4 min

COVID-19 vaccines have not caused an 8,200% increase in child deaths between 2021 and 2022, as has been claimed in a video posted on social media. That figure “completely misrepresents data”, according to a UK Office for National Statistics (ONS) spokesperson. During a five-minute speech, he claimed (at 1:34): “There is an 8,200% death increase in our children this year. So, from 2021 to 2022 there was an 8,200% death increase in our children. However, the claim in the video “completely misinterprets the data”, an ONS spokesperson told Reuters via email.

☆ Jim Cramer makes the bull case for consumer goods stocks
▼ + stars: | 2022-10-19 | by ( Krystal Hur | ) www.cnbc.com time to read: +1 min

CNBC's Jim Cramer on Wednesday told investors to consider adding shares of well-established consumer packaged-goods companies to their portfolios. "Nobody's championing what actually works: these old-line consumer packaged-goods names that we all know," he said. Cramer highlighted three companies' most recent quarterly results as examples of why investors should have such stocks on their shopping lists:"I bet we get something similar from Bristol-Myers , Coca-Cola and Eli Lilly [when they report earnings]," he said. Cramer also reiterated two points that he's made throughout this year: invest in boring companies with solid balance sheets and avoid money-losing companies that will likely struggle in a recessionary environment. Disclaimer: Cramer's Charitable Trust owns shares of Procter & Gamble, Johnson & Johnson and Eli Lilly.

☆ Johnson & Johnson Isn’t Rushing Into M&A
▼ + stars: | 2022-10-18 | by ( David Wainer | ) www.wsj.com time to read: 1 min

Most big pharma companies are moving with urgency to make acquisitions these days. The industry is sitting on a pile of cash from Covid-19 products, and many top companies need to replenish their pipelines as blockbuster drugs face generic competition this decade. Johnson & Johnson which on Tuesday reported third-quarter profit that beat analyst expectations while cutting its full-year sales guidance range, is no exception. Top-selling immunology drug Stelara, which has brought in over $7 billion in the first nine months of the year, is set to lose patent protection next year. And, like other big pharma companies, J&J is also extremely cash-rich, with about $34 billion on hand.

The Office of the Inspector General, under the leadership of Robert J. Devlin Jr., is one of multiple agencies investigating the officer's use of force. On Saturday, as it released that dramatic and potentially disturbing video, the watchdog stopped just short of calling Iurato a hero. The suspected gunman fired more than 80 rounds during the siege, the Office of the Inspector General said. The Office of the Inspector General said Sunday that it appears the officer's use of force was justified. The Bristol Police Union did not immediately respond to a request for its response to the bodycam footage.

☆ Wounded Connecticut officer shot, killed suspect who killed 2 colleagues in apparent ambush
▼ + stars: | 2022-10-15 | by ( The Associated Press | ) www.nbcnews.com time to read: +2 min

BRISTOL, Conn. — A Connecticut police officer who was wounded in an apparent ambush that killed two of his fellow officers fired the shot that killed the attacker, police said. Nathan Brutcher hasn’t been accused of playing any role in the attack. Nicholas Brutcher was a divorced father of two and a gun, hunting and fishing enthusiast, according to his social media pages. In a photo posted on both brothers’ Facebook pages in 2016, Nicholas Brutcher is pointing a handgun at the camera while others, including Nathan Brutcher, are holding rifles. Other photos show Nicholas Brutcher with a 10-point deer he shot and with fish he caught.

☆ Alaska cancels snow crab fishing for a year after the population mysteriously collapsed
▼ + stars: | 2022-10-15 | by ( Morgan Mcfall-Johnsen | ) www.businessinsider.com time to read: +4 min

Alaska canceled the Bering Sea snow crab fishing season for the first time ever on Monday. The snow crab stock looked promising in recent years, sparking hope amid the steep decade-long decline of Alaskan king crab. Yereth Rosen/ReutersScientists need to conduct further research to determine what exactly caused this year's snow crab population crash. Snow crabs had a baby boom, then disappearedA fisherman holds a snow crab in Kjoellefjord, Norway, on November 1, 2017. "Management of Bering Sea snow crab must now focus on conservation and rebuilding given the condition of thestock.

☆ 2 police officers killed in Connecticut shooting
▼ + stars: | 2022-10-13 | by ( Chantal Da Silva | Chantal Da Silva Is A Breaking News Editor For Nbc News Digital Based In London. | ) www.nbcnews.com time to read: +1 min

Two police officers were killed and one was in serious condition after an overnight shooting in Bristol, Connecticut, police said. The Connecticut State Police announced at around 3:30 a.m. ET it was investigating an officer-involved shooting in Bristol, about 20 miles southwest of Hartford, with injuries reported. Just over two hours later, police announced that two of the officers had been fatally shot, with one seriously injured. The department did not provide details on the circumstances of the shooting or whether any suspects had been identified or arrested.

Search resuls for: "BRISTOL"

25 mentions found